logo-loader
viewMediWound Ltd

MediWound climbs after reporting positive results from Phase 3 burn treatment clinical study

The Israeli company plans to submit a license application to the Food and Drug Administration in the second half of 2019

People working in lab
Results corroborated positive EU Phase 3 findings, according to MediWound

MediWound Ltd (NASDAQ:MDWD) rose Tuesday after reporting positive results from its Phase 3 US clinical study of its NexoBrid burn treatment.

The Israeli company said in a release the treatment met its primary endpoint and all secondary endpoints in the treatment of patients with deep partial thickness and full thickness thermal burns. MediWound plans to submit a license application to the Food and Drug Administration in the second half of 2019.

Shares of MediWound climbed $0.47, or 11%, to $4.85 in Tuesday’s premarket trading.

READ: MediWound enrolls in Phase 3 study for burn treatment, analysts reiterate Buy rating

“We are thrilled to announce these robust positive results across all endpoints,” Gal Cohen, president and CEO of MediWound, said in a statement.

Cohen added that the results corroborated positive European Union Phase 3 findings.

The primary endpoint was complete removal of eschar, the dead tissue found in a wound, according to MediWound. Secondary endpoints included reduction in the need for surgical eschar removal, earlier eschar removal and blood loss.

The study involves 44 burn centers, according to MediWound.

Contact Dennis Fitzgerald at [email protected]

Quick facts: MediWound Ltd

Price: 3.1 USD

NASDAQ:MDWD
Market: NASDAQ
Market Cap: $84.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Ontario's cannabis retail expansion plan gives cannabis stocks...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was 1.4% higher at 116.7 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF jumped 2.4% at C$9.55, while the OTCQX Cannabis index gained 0.6% to 434 points. Buds today are The Green...

2 days, 17 hours ago

2 min read